Open AccessImmunogenicity, Safety, and Clinical Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Spondyloarthritis (Preliminary Data)
Author(s) -
М. М. Баранова,
N. V. Muravyeva,
Б. С. Белов,
М. В. Черкасова,
Zh. G. Verizhnikova,
Т. В. Коротаева
Publication year - 2022
Publication title -
antibiotiki i himioterapiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.112
H-Index - 11
ISSN - 0235-2990
DOI - 10.37489/0235-2990-2022-67-1-2-39-44
Subject(s) - medicine , pneumococcal polysaccharide vaccine , vaccination , respiratory tract infections , ankylosing spondylitis , immunogenicity , immunology , gastroenterology , antibody , streptococcus pneumoniae , respiratory system , antibiotics , microbiology and biotechnology , biology , pneumococcal disease
Background . Immunosuppressive drugs are widely used for the treatment of patients with spondyloarthritis (SpA) to eectively control the activity of the disease. At the same time, the use of these drugs is associated with an increased risk of developing infections of the upper and lower respiratory tract, which can be prevented by vaccination. The aim of the study was to evaluate the immunogenicity, safety, and clinical ecacy of the 23-valent pneumococcal polysaccharide vaccine (PPV-23) in patients with SpA. Material and methods . The study included 54 patients with SpA: 39 with ankylosing spondylitis, and 15 with psoriatic arthritis. Most patients had a history of two or more cases of lower respiratory tract infections, 2 patients reported a monthly exacerbation of chronic sinusitis, one patient reported the development of otitis every 2–3 months. 72% of patients received immunosuppressive therapy at the time of inclusion in the study. PPV-23 was administered in the amount of 1 dose (0.5 ml) against the background of ongoing antirheumatic therapy. The level of antibodies to pneumococcal capsular polysaccharide was determined using the EIA PCP IgG kit (TestLine Clinical Diagnostics s.r.o., Czech Republic) at baseline, after 1, 3, and 12 months after vaccination. The tolerability of PPV-23, the eect of vaccination on SpA activity (according to the dynamics of the BASDAI index), and the incidence of upper and lower respiratory tract infections were assessed. Results . The concentration of antibodies to pneumococcal capsular polysaccharide was signicantly higher 1, 3, and 12 months after vaccination compared to baseline. There was no negative eect of vaccination on the activity of SpA and the emergence of «new» autoimmune disorders. The vaccine was well tolerated by 76% of patients., Only one patient developed pneumonia during the observation period. Patients suering from frequent sinusitis and otitis reported the absence of these infections after vaccination. Conclusions . Preliminary results of the study indicate sucient immunogenicity, safety, and clinical ecacy of PPV-23 in patients with SpA.